Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aegon Ltd. (AEG) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance

Aegon Ltd.Trade
Bio-Rad Laboratories, Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Aegon Ltd. vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Aegon Ltd. trades at $9.4 (market cap $14.16B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: Aegon Ltd. is the larger of the two by market cap, and Aegon Ltd. pays a 4.9% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

AEGBIO
Market Cap
$14.16B$9.39B
Sector
FinancialsHealth
52-Week High
$9.53$356.25
52-Week Low
$6.79$241.71
Enterprise Value
$15.31B$9.14B
Dividend Yield
4.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aegon Ltd.

AEG trades at $9.53, up 0.74% on the day, with a bullish technical signal driven by moving averages. The company reported revenue of $19.52 billion in 2024 with a net income margin of 3.64%, and recent earnings show mixed results with beats in Q2 and Q3 2025 but a miss in Q4. A dividend of $0.25 is scheduled for July 2026. The balance sheet shows total assets of $327.39 billion and a debt-to-asset ratio improving to 1.46 in 2024.

The outlook is cautiously optimistic with a P/E of 13.74 and P/S of 0.58 suggesting reasonable valuation, but risks include volatile cash flows and competitive pressures. Analyst sentiment is mixed with 27.78% buy ratings, highlighting potential for growth amid execution challenges.

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

Returns comparison

Trailing returns across standard periods

About Aegon Ltd.

Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.

Read more on AEG

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO